QYUNS-B (02509) saw its stock price increase by more than 3%. As of the latest update, the share price rose by 3.47% to HK$17.28, with a trading volume of HK$4.2084 million.

On May 8, according to an announcement from the company, QYUNS-B announced the recent completion of a $165 million crossover financing round. The proceeds will be used to advance the development of candidate drugs, including WIN027 (QYUNS-B's R&D code: QX027N) and WIN378.

Since its establishment in January 2025, Windward Bio has raised a cumulative total of $365 million in funding. QYUNS-B entered into a collaboration with Windward Bio regarding QX027N in December 2025.

Currently, WIN027 is in the Phase I clinical research stage, with data readout expected to be completed by the end of 2026. This financing round will support WIN027's planned proof-of-concept studies targeting respiratory and dermatological indications, which are scheduled to commence in the fourth quarter of 2026.

Additionally, Windward Bio's lead project, WIN378, is a next-generation fully human monoclonal antibody targeting TSLP, offering the potential for ultra-long-acting treatment with dosing only twice a year. WIN378 is currently undergoing the Phase II/III POLARIS clinical trial for the treatment of asthma. The Phase II dose-escalation stage of the POLARIS trial has completed patient enrollment, with preliminary data expected to be released in the second half of 2026.